Literature DB >> 29684459

Treatment of Dyslipidemia in Common Liver Diseases.

Elizabeth K Speliotes1, Maya Balakrishnan2, Lawrence S Friedman3, Kathleen E Corey4.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29684459      PMCID： PMC6558967          DOI： 10.1016/j.cgh.2018.04.023

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  57 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

2.  The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD).

Authors:  Tadashi Shiwa; Yoshiya Kawanami; Tomoko Yokoyama; Akihiko Moritani; Masatoshi Hashimoto; Tohru Gotoh
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2011-08

Review 3.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

Authors:  Rossana M Calderon; Luigi X Cubeddu; Ronald B Goldberg; Eugene R Schiff
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

4.  Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.

Authors:  Huan Yan; Bo Peng; Yang Liu; Guangwei Xu; Wenhui He; Bijie Ren; Zhiyi Jing; Jianhua Sui; Wenhui Li
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

5.  Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study.

Authors:  P Riley; D Sudarshi; M Johal; A Benedict; J Panteli; M Crook; J O'Donohue
Journal:  Int J Clin Pract       Date:  2008-01-14       Impact factor: 2.503

6.  Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

Authors:  P André; F Komurian-Pradel; S Deforges; M Perret; J L Berland; M Sodoyer; S Pol; C Bréchot; G Paranhos-Baccalà; V Lotteau
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 7.  Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.

Authors:  Anders Asberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Authors:  Mark W Russo; Jay H Hoofnagle; Jiezhun Gu; Robert J Fontana; Huiman Barnhart; David E Kleiner; Naga Chalasani; Herbert L Bonkovsky
Journal:  Hepatology       Date:  2014-05-13       Impact factor: 17.425

9.  Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation.

Authors:  C L Donovan; P A Marcovitz; J D Punch; D S Bach; K A Brown; M R Lucey; W F Armstrong
Journal:  Transplantation       Date:  1996-04-27       Impact factor: 4.939

10.  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

Authors:  Vassilios G Athyros; Olga Giouleme; Emmanouel S Ganotakis; Moses Elisaf; Konstantinos Tziomalos; Themistoklis Vassiliadis; Evangelos N Liberopoulos; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318
View more
  10 in total

1.  Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects.

Authors:  Robert T Streeper; Elzbieta Izbicka; Christopher Louden
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications.

Authors:  Christopher Kasia; Steven J Scaglione
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-04-30

Review 3.  Statins Show Promise Against Progression of Liver Disease.

Authors:  Prashanth Francis; Lisa M Forman
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-12-20

Review 4.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

Review 5.  Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.

Authors:  Nicholas W S Chew; Cheng Han Ng; Mark Dhinesh Muthiah; Arun J Sanyal
Journal:  Curr Atheroscler Rep       Date:  2022-05-04       Impact factor: 5.967

6.  Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.

Authors:  Fang Liu; Zhao-Bin Cai; Jin-Song Huang; Wen-Yan Yu; Hai-Ying Niu; Yan Zhang; Dong-Ming Sui; Fei Wang; Li-Zhi Xue; Ai-Fang Xu
Journal:  Pathog Dis       Date:  2020-06-01       Impact factor: 3.166

Review 7.  Statins in Non-alcoholic Steatohepatitis.

Authors:  Jose D Torres-Peña; Laura Martín-Piedra; Francisco Fuentes-Jiménez
Journal:  Front Cardiovasc Med       Date:  2021-11-24

8.  Protective Effects of A. sativa against Oxidative Stress-Induced Liver Damage in Ovariectomized Mice.

Authors:  Mabrouka Ltaif; Manel Gargouri; Ahlem Soussi
Journal:  Biomed Res Int       Date:  2021-07-15       Impact factor: 3.411

9.  Partial Replacement of Dietary Fat with Krill Oil or Coconut Oil Alleviates Dyslipidemia by Partly Modulating Lipid Metabolism in Lipopolysaccharide-Injected Rats on a High-Fat Diet.

Authors:  Hee-Kyoung Son; Bok-Hee Kim; Jisu Lee; Seohyun Park; Chung-Bae Oh; Sunyoon Jung; Jennifer K Lee; Jung-Heun Ha
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

10.  An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL.

Authors:  Augustin G L Vannier; Amanda PeBenito; Esperance Schaefer; Russell P Goodman; Jay Luther; Vladislav Fomin; Raymond T Chung
Journal:  Clin Exp Med       Date:  2021-07-01       Impact factor: 3.984
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.